Background: Intravenous acetaminophen is commonly administered as an adjunctive
| INTRODUCTION
Obesity among children and adolescents in the United States has increased threefold in the past 30 years with 15.5% of children and adolescents currently estimated to be obese (body mass index
[BMI] ≥95th percentile for age). 1 Metabolic and bariatric surgery has been shown to be effective in reducing excess weight in severely obese patients; defined as BMI >120% of the 95th percentile and estimated to affect approximately 4%-7% of the pediatric population in the United States. 2 Postoperative pain control can be challenging following metabolic and bariatric surgery, given the associated co-morbid conditions, including sleep disordered breathing. While opioids are commonly used to provide analgesia after bariatric surgery, their use can predispose to respiratory insufficiency, exacerbation of obstructive sleep apnea, and postoperative ileus. [3] [4] [5] [6] Adjunctive drugs, including nonsteroidal antiinflammatory drugs and acetaminophen, are frequently used to provide multimodal analgesia while decreasing opioid requirements during the perioperative period. 3 A key component of multimodal analgesia is the achievement of adequate effect site concentrations. However, acetaminophen dose is commonly based on a manufacturer-recommended maximum single dose of 1000 mg, with a recommended maximum total dose of 4000 mg over a period of 24 hours (Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA). 7 Those doses were determined by concerns regarding hepatotoxicity caused by chronic administration rather than by pharmacokinetic-pharmacodynamic considerations. 8 The best size descriptor for determination of acetaminophen dose in obese and severely obese adolescents remains uncertain.
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The objective of this study was to investigate acetaminophen serum concentrations following the administration of a single intravenous dose of the manufacturer's recommended maximum of 1000 mg in obese adolescents and young adults following sleeve gastrectomy. Pharmacokinetic analysis of time-concentration profiles included assessment of size descriptors 9 for obese adolescents in order to predict a dose that might achieve a target concentration of 10 mg·L −1 at steady-state. 
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| MATERIALS AND METHODS
What this study adds
• A single dose of acetaminophen (1000 mg) resulted in serum concentrations below the target concentration of 10 mg·L −1 in all patients within 2 hours after administration. The dose that achieves a target concentration of 10 mg·L −1 in the effect compartment is better predicted using total body weight with allometric scaling.
concentration 10-20 minutes after administration) was performed after 11 patients were enrolled, and study enrollment was curtailed because the conditional power to detect a 2.5 μg·mL −1 deficit from the recommended limit at this time point was found to be <1% on a one-sided t-test.
Venous samples (3 mL) for acetaminophen concentration assay were drawn in the postanesthesia care unit or on the inpatient ward by a member of the research team. The assay was performed by the hospital laboratory using the Ortho Vitros reagent (Ortho Clinical Diagnostics, Jersey City, NJ, USA), which uses hydrolysis of acetaminophen by aryl acyl amidase to p-aminophenol. The lower limit of quantitation of the assay was 10 μg·mL
. The precision of the assay was reported as an average of 1.8% with a range of 1.1%-2.5%.
| Pharmacokinetic analysis
| Population parameter estimations
A two-compartment mammillary model was used to investigate acetaminophen pharmacokinetics using clearance (CL), intercompartment clearance (Q), central volume of distribution (V1), and peripheral volume of distribution (V2). Population parameter estimates were obtained using a nonlinear mixed effects model (NONMEM 7.4, ICON Development Solutions, San Antonio, TX, USA). The population mean parameters, between subject variance and residual variance were estimated using the first-order conditional, Laplace estimation method with interaction using ADVAN 3 TRANS 4. Data below the lower limit of quantification were accommodated using the M3 method described by Beal. 13 Convergence criterion was three significant digits.
The population parameter variability is modeled in terms of random effect (η) variables. Each of these variables is assumed to have mean 0 and a variance denoted by ω 2 , which is estimated.
The population parameter variability in model parameters was modeled with an exponential model. We report the estimate of ω for each variability component expressed as a percentage because these quantities are approximate coefficients of variation for a log normal distribution.
The covariance between two elements of η (eg, CL and V) is a measure of statistical association between these two variables. The covariance of clearance and distribution volume variability was estimated. Residual unidentified variability (RUV) was modeled using both proportional and additive residual errors. The between subject variability (η RUV ) of the RUV was also estimated. The parameter values were standardized for a body size of 70 kg total body weight (TBW) using an allometric model. 
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Total drug clearance (CL) may be expected to scale with a power of ¾ with the allometric model:
where CLstd is the population estimates for CL.
We further investigated size using normal fat mass (NFM) where NFM is X in the above equation. 18 NFM is an extension of the concept of predicted normal weight 19 with a parameter (Ffat) which accounts for different contributions of fat mass (ie, TBW minus fatfree mass, FFM): . At 10-20 minutes after the infusion, the acetaminophen serum concentration was 17 (SD 4) μg·mL
, but rapidly declined. The acetaminophen serum concentration was lower than the lower limit of the recommended target 10 μg·mL −1 within 80-100 minutes in all 11 patients (Table 1) 
| DISCUSSION
Adolescents given acetaminophen (1000 mg) do not achieve serum concentrations similar to those observed in their nonobese counterparts. Acetaminophen concentrations were undetectable using the standard assay at the hospital 2 hours after administration. Doses bigger than 1 g are required for obese adolescents to achieve equivalent concentrations as those achieved in nonobese adolescents.
Determination of dose in obese adolescents is difficult because clearance has a nonlinear relationship with total body weight and fat mass makes a contribution to volume of distribution. Dose calculation is further compromised by hepatotoxicity concerns reported after acetaminophen use.
The size model that best described pharmacokinetics was normal fat mass (NFM) used in conjunction with allometric theory. 18 The parameter Ffat that accounts for different contributions of fat mass to volumes was 0.88; an Ffat of 1 is equivalent to total body weight.
Total body weight is a better parameter for estimation of acetaminophen clearance than fat-free mass (ie, lean body mass) and should be used to estimate dose. This finding is similar to other reports of acetaminophen clearance in adults and to that described for propofol in children and adults where TBW used with allometric theory is the preferred metric.
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The majority of adolescents undergoing bariatric surgery are female in the United States, 26 and study recruitment reflects this female dominance, whereas male patients were not intentionally excluded from enrollment. There are data suggesting that women taking steroid oral contraceptives have an increased glucuronidation of acetaminophen of up to 50%, consistent with observations that both pregnancy and oral contraceptives use has effect on intravenous acetaminophen disposition. 27, 28 This may be driven by oestradiol. 29 Clearance in pregnant women is increased, but by a reduced magnitude than in early reports, which did not account for appropriate size scaling. 30 Those authors were unable to show that sex was a covariate. 30 We identified two adolescents who were taking oral contraceptives in this current study. Subgroup analysis was not possible in such a small cohort; although it may have contributed to variability noted in clearance estimates.
The clearance pharmacokinetic parameter estimate (CL 10.6 L·h·70 kg ). [31] [32] [33] [34] [35] Clearance scales with total body weight in a nonlinear relationship, consistent with allometric theory. 36 A single dose of 2250 mg is required in a 125 kg adolescent to achieve similar effect site concentrations as that achieved by a nonobese, 50 kg adolescent given 1000 mg. Regular dosing of 1000 mg 6 hourly will only achieve a mean effect site concentration of 8. , which is well above the therapeutic target for analgesia of 10 μg·mL −1 , thereby providing a wide therapeutic index.
The toxic metabolite of acetaminophen, N-acetyl-p-benzoquinone imine (NAPQI), is formed by the cytochrome, CYP2E1. NAPQI binds to intracellular hepatic macromolecules to produce cell necrosis and damage. Hepatotoxicity is dependent on the balance between the rate of NAPQI formation, capacity of the safe elimination pathways of sulfate and glucuronide production, and the initial content and maximal rate of synthesis of hepatic glutathione that mops up NAPQI. Understanding of these relationships in the obese individual is lacking, and it is this lack of understanding, rather than pharmacokinetic knowledge, that restricts dosing. Significant hepatic and renal disease, malnutrition, and dehydration may increase the propensity for toxicity, although the role of hepatic disease is debated. Mild liver dysfunction has no impact on acetaminophen clearance nor does it predispose to hepatotoxicity. 37 Clearance is similar in those with and without nonalcoholic liver disease. 38 Medications that induce the NAPQI formation (eg, phenobarbitone, phenytoin, and rifampicin) may also increase the risk of hepatotoxicity. 39 The influence of obesity, if any, on acetaminophen toxicity is unknown.
Obesity has been considered as an inflammatory disease and liver function tests and inflammatory markers may be elevated in that cohort prior to surgery. 40 Acetaminophen use and surgery are commonly associated with an increase in hepatic function tests but there is no evidence that these markers can be used as an early indicator of acetaminophen-induced hepatotoxicity. [41] [42] [43] CYP2E1 activity F I G U R E 1 A visual predictive check showing predictions adequate for data. All plots show median and 90% confidence intervals (solid and dashed lines). Left-hand plot shows all observed concentrations. Right-hand plot shows percentiles (10, 50, 90) for observations (lines with symbols) and predictions (lines) with median (pink) and 95% confidence intervals for prediction percentiles (blue-shaded areas)
F I G U R E 2 Simulation shows serum and effect site time-concentration profiles for an adolescent 50 kg given acetaminophen 1000 mg and an adolescent 125 kg given acetaminophen 1000 mg. An acetaminophen dose of 2250 mg is required in an obese adolescent to achieve similar concentrations to a nonobese adolescent. An effect site equilibration half time of 0.7 h was assumed.
may be increased in obese patients, 40 but there is also commonly an increased glucuronide clearance and so less substrate is available for CYP2E1 metabolism. The impact of any increased CYP2E1 activity, duration of effect, production of NAPQI, and differences in glutathione production remain poorly quantified.
The assay had a LLOQ that was similar to the target concentration for the analgesic use of acetaminophen. This clinical study demonstrates that concentrations were below that target at 2 hours both as observed and as PK model predicted. Serum concentration is used as a marker for hepatotoxicity after single dose administration. 44 Dosing per-kilogram can result in relative overdose in obese adolescents because clearance has a nonlinear relationship with weight that is characterized using allometry.
ETHICAL APPROVAL
The study was approved by the Institutional Review Board of Nationwide Children's Hospital (IRB15-00471).
CONF LICT OF I NTEREST
Brian Anderson sits on the Editorial Board of the journal, Pediatric
